Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alfacell (ACEL) -- Ignore unavailable to you. Want to Upgrade?

To: Tom DuBois who wrote (1412)	6/23/1998 12:37:00 PM
From: Gil Kempenich	Read Replies (1) \| Respond to of 1533

Tom, Once the FDA gives the go-ahead for NDA filing, the likelihood of agreements goes up. Once NDA is filed, it goes up some more. With FDA approval, it goes up even more. However by then I would expect an agreement in place. I also expect investor interest to go up in the same way. Institutions and pharma companies are all waiting for results, to reduce risk. Makes lots of sense. There is no incentive at this point for pharmas to come ot the plate, when we are so close to a reduced risk situation. Gil